Should I Buy IVVD? IVVD 2026 Analysis

Should You Buy Invivyd Inc (IVVD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

1.850

1 Day change

-3.65%

52 Week Range

3.070

Analysis Updated At

2026/01/29

Buy now for a short-term rebound setup. IVVD is extremely oversold (RSI-6 ~14) and trading just above key support (S1 ~1.898 vs. close ~1.925), which creates a favorable immediate entry for an impatient trader looking for a mean-reversion bounce. This is not a trend-following long entry (MACD is still deteriorating), but the current price location + oversold condition offers the best near-term reward potential versus nearby support.

Technical Analysis

Trend/structure: Near-term trend remains bearish (MACD histogram -0.067 and negatively expanding), but momentum is stretched to the downside (RSI-6 ~14.46 = extreme oversold), often preceding sharp snapback rallies. Levels: Price ~1.925 is sitting on first support (S1 1.898). If it holds, the first upside magnet is the pivot ~2.206, then R1 ~2.515. If support fails, next major support is S2 ~1.707. Moving averages: Converging MAs suggest the selloff may be late-stage, but confirmation would be a reversal and reclaim of the pivot. Pattern-based projection: Similar candlestick-pattern cohort implies ~+3.51% over the next week and ~+17.2% over the next month (despite near-flat next-day expectation). **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): no signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Positioning/sentiment: Open interest put-call ratio 0.88 is mildly call-leaning/neutral, but the option volume put-call ratio 2.78 is strongly bearish intraday (puts dominated trading flow). Activity: Volume is elevated (today vs 30D avg ~335%), signaling heightened speculation/positioning. Volatility: IV is very high (30D IV ~169.6%) but IV rank/percentile are relatively low (rank ~14, percentile ~19.6), suggesting IV is high in absolute terms but not extreme versus its own recent history—consistent with a chronically high-vol small-cap biotech. Net read: Options flow is cautious-to-bearish short-term (heavy put volume), which can also coincide with capitulation-type selling and near-term bounces when combined with extreme RSI.

Technical Summary

Sell

Buy

Positive Catalysts

Technicals: Extreme oversold RSI near key support favors a fast mean-reversion bounce; Pattern-based stats point to modest 1-week and strong 1-month upside.
Fundamental narrative: Pipeline progress (e.g., REVOLUTION program for VYD2311 previously cited by Street) remains a longer-dated upside driver.
Profitability quality: Very high gross margin (~91.7%) supports the idea that revenue can translate well if scale improves.

Neutral/Negative Catalysts

Downtrend momentum: MACD is still worsening, so price can stay weak even if oversold.
Derivatives sentiment: Put volume heavily outweighing call volume (put-call volume ratio 2.78) reflects bearish near-term positioning.
Flows: Hedge funds are selling aggressively (selling amount up ~433% QoQ), a notable headwind.
No near-term headline support: No news in the past week, so fewer obvious immediate catalysts for a sustained breakout.
Political/influential trading: No recent congress trading data available; insiders reported as neutral with no significant recent trend.

Financial Performance

Latest quarter: 2025/Q3. Growth: Revenue rose to ~$13.13M (+41.17% YoY), a clear top-line improvement. Profitability: Net income fell to about -$10.47M (loss widened YoY) and EPS dropped to -$0.06 (worse YoY), meaning growth is not yet translating into improved earnings. Margins: Gross margin ~91.71% (slightly higher YoY), which is strong but currently outweighed by operating costs/R&D.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent Street trend: Mixed. H.C. Wainwright (2025-10-31) reiterated Buy and raised PT to $10 (from $5) on the REVOLUTION clinical program launch, framing it as an inflection point. Later, D. Boral Capital (2025-11-25) downgraded to Hold (no PT) after a $125M equity offering and with its prior $2 PT already achieved. Wall Street pros: Potential clinical/regulatory inflection points and a much higher bull-case target from a covering firm. Wall Street cons: Dilution/capital raise overhang and at least one firm seeing current prices as already reflecting near-term expectations.

4 Analyst Rating

Wall Street analysts forecast IVVD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IVVD is 10 USD with a low forecast of 10 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 1.920

Low

Averages

High

Current: 1.920

Low

Averages

High

Boral Capital

D. Boral

Buy

Hold

downgrade

AI Analysis

2025-11-25

Reason

Boral Capital

D. Boral

Price Target

AI Analysis

2025-11-25

downgrade

Buy

Hold

Reason

D. Boral Capital downgraded Invivyd to Hold from Buy with no price target after the company announced the nomination of its next-generation RSV antibody VBY329 with IND readiness targeted for the second half of 2026 and concurrently strengthened its capital position through a $125M equity offering. With the fundraise anticipated in the firm's prior modeling, the transaction does not alter its valuation framework, but with its previous $2 price target achieved, it now shifts to Hold as the shares more fully reflect pipeline and balance sheet expectations.

H.C. Wainwright

Patrick Trucchio

Buy

maintain

$5 -> $10

2025-10-31

Reason

H.C. Wainwright

Patrick Trucchio

Price Target

$5 -> $10

2025-10-31

maintain

Buy

Reason

H.C. Wainwright analyst Patrick Trucchio raised the firm's price target on Invivyd to $10 from $5 and keeps a Buy rating on the shares after the company unveiled the REVOLUTION clinical program for VYD2311, a vaccine-alternative monoclonal antibody for COVID-19 prevention. The firm views the REVOLUTION launch as a "meaningful inflection point" that strengthens Invivyd's regulatory and commercial narrative.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IVVD

Unlock Now

IVVD Should I Buy

IVVD Should I Buy

Should You Buy Invivyd Inc (IVVD) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch